Abbott, Reata ally once again, this time to develop AIMs for various conditions; deal ends
Oral anti-inflammatories developer Reata Pharmaceuticals Inc. has enlisted the help of Abbott Laboratories Inc. to help develop and commercialize second-generation oral anti-oxidant inflammation modulators (AIMs).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.